RxDoctor Payments Data

Rene Disotuar Abad, MD

General Practice · Tampa, FLNPI 1780019026

Payments from drug & device makers

$2,162in general payments, 2019–2025

Across 69 payments — averaging $31.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$503
  • Novo Nordisk$406
  • Johnson & Johnson$360
  • Lilly USA, LLC$326
  • Abbott$146
  • Otsuka America Pharmaceutical, Inc.$122
  • plus $299 from 7 others

What the payments were for

  • Food & beverage$2,155100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,162 in reported general payments places this provider in the 85th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$27,475
Medicare patients
88
Services billed
515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$105,730
EliquisApixaban62$78,097
TrulicityDulaglutide44$66,748
JardianceEmpagliflozin36$53,032
MounjaroTirzepatide30$36,106
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$27,649
FarxigaDapagliflozin Propanediol22$24,479
JanuviaSitagliptin Phosphate13$20,140
EntrestoSacubitril/Valsartan13$18,526
LinzessLinaclotide16$16,134
Tresiba Flextouch U-200Insulin Degludec17$12,954
MyrbetriqMirabegron11$8,014
Spiriva RespimatTiotropium Bromide12$6,106
Atorvastatin Calcium688$5,734
SymbicortBudesonide/Formoterol Fumarate26$5,609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$406$108,43387 claims
Lilly USA, LLCTrulicity, Mounjaro$326$102,85574 claims
PfizerEliquis$40$78,09762 claims
Boehringer IngelheimJardiance, Spiriva Respimat$45$59,13848 claims
GSKTrelegy Ellipta, Breo Ellipta$503$32,76646 claims
AstraZenecaFarxiga, Symbicort$66$30,08848 claims
AbbVieLinzess, Lumigan, Synthroid$34$21,42143 claims
NovartisEntresto$17$18,52613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,901 general practice providers in Florida.

Other general practice in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →